Rocketvax Achieves Major Breakthrough in Live-Attenuated SARS-CoV-2 Vaccine Development

Live attenuated SARS-CoV-2 vaccine OTS-228 demonstrates efficacy, safety, and stability in preclinical model

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Rocketvax and HALIX Collaborate to Advance the VIRUFLEX(TM) Platform and Next-Generation Nasal COVID-19 Vaccine

High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters

Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)

Promising Next-Generation SARS-CoV-2 Live Vaccine Demonstrates Remarkable Safety, Protection, and Immunity Profile in Pre-Clinical Studies

Rocketvax Announces Collaboration with the US National Institutes of Health (NIH) for Clinical Trial of Nasal, Live-Attenuated NextGen SARS-CoV-2 Vaccine

New study on the benefits of COVID-19 nasal spray vaccination published in "Nature Communications"

Finanz und Wirtschaft: RocketVax could become the new Moderna

Rocketvax AG selected to participate in SIX Swiss Exchange Sparks IPO Academy

Impfen wir bei Covid-19 bald über die Nase?

Nasal vaccine against coronavirus further improved

New vaccine concept against SARS-CoV-2 successfully tested

Swiss Rockets AG Welcomes Three New Key Members To The Team